Epsolay Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Epsolay Availability in 2026

Epsolay (Benzoyl Peroxide cream, 5%) has established itself as a valuable addition to the rosacea treatment armamentarium since its FDA approval in April 2022. As the first and only microencapsulated Benzoyl Peroxide formulation approved for inflammatory lesions of rosacea in adults, it fills a unique therapeutic niche.

However, your patients may be reporting difficulty filling their Epsolay prescriptions. This briefing covers the current availability landscape, prescribing implications, cost considerations, and tools to help your patients access this medication.

Timeline: Epsolay's Path to Market

Understanding Epsolay's background helps contextualize its current market position:

• April 2022: FDA approved Epsolay (NDA 214510) under the 505(b)(2) pathway for treatment of inflammatory lesions of rosacea in adults
• June 2022: Commercial availability began in the United States
• 2022-2024: Sol-Gel Technologies marketed the product; Galderma/Mayne Pharma later took over U.S. distribution
• 2025-2026: Product remains brand-only with no generic competitors; availability challenges persist at many retail pharmacy locations

Prescribing Implications

Epsolay's clinical profile supports its use in appropriate patient populations, but access barriers necessitate proactive planning:

Clinical Considerations

• Indication: Inflammatory lesions (papules and pustules) of rosacea in adults 18 and older
• Dosing: Pea-sized amount applied once daily to each facial zone (forehead, chin, nose, each cheek) on clean, dry skin
• Onset of action: Clinical improvement typically observed within 3-4 weeks, with continued improvement through 12 weeks
• Key differentiator: Microencapsulated delivery system reduces the irritation typically associated with Benzoyl Peroxide application on rosacea-sensitive skin

Interaction Awareness

While Epsolay has a favorable interaction profile as a topical agent, remind patients to avoid concurrent use with:

• Topical Tretinoin: Benzoyl Peroxide can oxidize and inactivate Tretinoin
• Topical Dapsone: May cause temporary yellow-orange skin discoloration
• Other drying or peeling topical agents (Salicylic Acid, Sulfacetamide) — may increase irritation

For complete interaction guidance, see our Epsolay drug interactions reference.

Safety Profile

Common adverse reactions include application site pain, erythema, pruritus, dryness, scaling, stinging/burning, and swelling. Serious but rare events include hypersensitivity reactions (anaphylaxis, angioedema, urticaria). Advise patients about photosensitivity and the importance of sun protection.

There is no boxed warning. The product is contraindicated only in patients with known hypersensitivity to Benzoyl Peroxide or any formulation component.

Current Availability Picture

Epsolay is not on the FDA drug shortage list as of early 2026. The availability challenges providers and patients encounter are demand-side rather than supply-side:

• Pharmacy stocking: Many retail chain pharmacies do not routinely stock Epsolay due to low prescription volume and high unit cost ($545-$1,034 per 30g pump)
• Insurance barriers: Prior authorization and step therapy requirements reduce the fill rate, further decreasing pharmacy incentive to stock
• Distribution: The product is available through standard pharmaceutical wholesalers; pharmacies can special-order it within 1-3 business days

Cost and Access Considerations

Cost remains the primary access barrier for many patients. Here's the current pricing landscape:

• Average wholesale price: Approximately $545-$1,034 per 30g pump
• GoodRx coupon: Approximately $525
• Mayne Pharma Patient Savings Card (commercial insurance): As low as $0 copay
• Mayne Pharma Patient Savings Card (uninsured): As low as $75

The Mayne Pharma Patient Savings Card is particularly valuable and should be discussed with patients at the point of prescribing. You can direct patients to epsolay.com/savings-and-support or to our patient-facing guide on saving money on Epsolay.

Important note: Government insurance (Medicare, Medicaid, Tricare) patients are not eligible for manufacturer copay cards. These patients may benefit from patient assistance programs through NeedyMeds.org or RxAssist.org.

Tools and Resources for Your Practice

Several resources can help streamline Epsolay access for your patients:

Medfinder for Providers

Medfinder allows providers and staff to check real-time pharmacy stock for Epsolay and direct patients to pharmacies that have it available. This reduces patient frustration and pharmacy call volume.

Prior Authorization Support

When submitting prior authorization requests, emphasize:

• Epsolay's unique mechanism (microencapsulated BPO — no therapeutic equivalent)
• Patient's history of failure or intolerance with generic alternatives (Metronidazole, Azelaic Acid)
• Clinical rationale for this specific formulation vs. standard BPO products

Samples and Bridges

If your practice stocks Epsolay samples, consider providing a bridge supply while patients navigate insurance approval or pharmacy sourcing. This helps maintain treatment continuity.

Preferred Pharmacy Routing

Identify 1-2 local pharmacies (ideally independent or specialty dermatology pharmacies) that reliably stock or can quickly order Epsolay. Route prescriptions to these locations by default to reduce fill failures.

Alternative Treatment Options

When Epsolay is not accessible or clinically appropriate, evidence-based alternatives include:

• Metronidazole 0.75%-1% (generic): First-line for many insurers; applied once or twice daily
• Azelaic Acid 15% gel/foam (Finacea or generic): Twice daily application; anti-inflammatory and antimicrobial
• Ivermectin 1% cream (Soolantra): Once daily; targets Demodex mites and inflammation
• Minocycline 1.5% foam (Zilxi): Once daily topical antibiotic; newer option
• Oral Doxycycline (sub-antimicrobial dose, 40mg modified-release): Oracea; anti-inflammatory without antibiotic resistance concerns

See our comprehensive alternatives guide for patient-facing information you can share.

Looking Ahead

Several developments may improve Epsolay access over time:

• Expanded awareness: Growing prescriber familiarity and patient demand should improve pharmacy stocking patterns
• Formulary evolution: As clinical evidence accumulates and payer negotiations continue, formulary positioning may improve
• Generic pipeline: While no generic is imminent, eventual patent expirations will likely expand access and lower cost
• Rosacea pipeline: New treatments in development may provide additional options for patients who can't access Epsolay

Final Thoughts

Epsolay remains a clinically differentiated treatment for papulopustular rosacea with a favorable safety profile and once-daily convenience. While access challenges persist in 2026, proactive steps — including savings card enrollment, preferred pharmacy routing, and tools like Medfinder — can meaningfully improve the patient experience.

For additional provider resources, including a guide on helping patients find Epsolay in stock and information on helping patients save money on Epsolay, visit our provider section.